Navigation Links
Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
Date:1/31/2008

PRINCETON, N.J., Jan. 31 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it is scheduled to present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference at 9:20 a.m. ET on Thursday, February 7, 2008. The event will be webcast live and will be available in the Investor Relations section of the Medarex Web site at http://www.medarex.com. An archived edition of the presentation will be available following the event.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 30 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase III clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its Web site at http://www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc.
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
2. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
3. Medarex to Present at the JPMorgan Small/Mid Cap Conference
4. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
5. 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Millennium Presentation
6. Womans Day Presents the 5th Annual Red Dress Awards Honoring Women Who Are Leaders in the Fight Against Heart Disease
7. Moog to Present at Cowen & Co. Aerospace and Defense Conference on February 5, 2008
8. Center for Science Writings presents: Big Fat Lies: The Truth about Diet, Exercise and Obesity
9. Stryker to Present at Investor Conference
10. AMICAS to Present at UBS Global Healthcare Services Conference
11. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- In people with sex addiction, pornography affects the ... in drug addicts as they consume drugs, a new ... activity between patients who have compulsive sexual behavior and ... study author Dr. Valerie Voon, of the University of ... Voon,s research involved 19 men with sex addiction ...
(Date:7/11/2014)... (HealthDay News) -- U.S. health officials have concluded that ... live anthrax during a safety mishap last month. ... officials have announced a moratorium on the transfer of ... In a report issued Friday, the CDC outlined ... a similar incident doesn,t occur again. Last month, as ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 The ... Supplements, Specialty Nutrients, Animal Feed), Applications (Regular, Therapeutic, ... - Global Trends & Forecasts to 2019 ” ... an analysis and forecasting of the market value ... identifies the driving and restraining factors for the ...
(Date:7/11/2014)... to a new market research report “Internet of Things ... Bluetooth, Wi-Fi, NFC, RFID), Application Vertical (Building Automation, Consumer, ... - Global Trends & Forecasts to 2014 - 2020”, ... $1029.5 Billion in 2013, and is expected to reach ... 4.08% from 2014 to 2020. , Browse more ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Biostimulants are ... growth in turf and ornamentals. These also help turf ... improve length of roots. Turf, ornamentals, and flowers appear ... Therefore, this usage has increased from the last few ... turf and ornamentals is Europe, with around 40% share ...
Breaking Medicine News(10 mins):Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3
... of blood tests over skin tests for detecting people ... effective, reliable and therefore holds promise in detecting latent ... dormant TB infection never actually get a full blown ... cases and offer treatment, which would take the pursuit ...
... a breach of trust if the court orders to release a ... and a patient.// The hospital said that it would do everything ... had an abortion at 32 weeks' pregnancy. She plans to take ... Appeal ordered that the woman's files be released to the Medical ...
... more number of bus drivers and conductors in India are ... of the bus conductor Ravindra Kamble (34). //Statistics show that ... year have been tested positive for HIV. The BEST’s HIV ... the previous year. ,He took the initiative for ...
... stem cell products through an IV line, in the years ... heart muscle in patients who have experienced heart attack for ... distinct advantage of the procedure is that intravenous infusion of ... a healthy donor can reverse heart tissue damage, elimininating the ...
... about increased risk of birth defects associated with letrozole, ... commonly given for infertility treatment has been settled//. A ... birth defects associated with letrozole is very similar to ... for infertility for more than 40 years that is ...
... that are associated with the menopause and dry eye is ... that the symptom is associated with the menopause or peri-menopause. ... risk of infection or visual impairment. ,The survey, sponsored ... percent of menopausal and peri-menopausal women reported that they experience ...
Cached Medicine News:Health News:Bad Publicity for the Hospital With Respect To Dwarfism Abortion Case 2Health News:Stem Cell Therapy Regenerates Heart Muscle In Heart Attack Patients 2Health News:Dry Eye Is A Symptom Of Menopause 2
(Date:7/11/2014)... According to a new market ... (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) - Global ... the global endoscopy devices market was valued at USD ... at a CAGR of 6.8% from 2013 to 2019, ... in 2019. Browse the full Endoscopy Devices Market ...
(Date:7/10/2014)... MUMBAI, India , July 11, 2014 /PRNewswire/ ... the treatment of cancer are being highlighted in ... Mumbai from 10-12 July, 2014.  Renowned ... meeting to share best practices and exchange knowledge ... more precise, accurate and efficient. ...
(Date:7/10/2014)... SAN DIEGO , July 10, 2014  RESMED INC. ... report its fourth quarter and fiscal year ended June 30, ... York Stock Exchange market close. A press release with ResMed,s ... and the company will host a webcast to discuss operating ... scheduled to begin at 1:30 p.m. US Pacific Time and ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... , REDWOOD CITY, Calif., ... its relationship and the signing of its second agreement this ... drug manufacturer. The new agreement covers three undisclosed pharmaceutical ... January 7. , Under the new agreement, Teva will use ...
... Md., Dec. 1 Micromet, Inc. (Nasdaq: MITI ), ... of cancer, inflammation and autoimmune diseases today announced that Bayer ... collaboration and license agreement entered into on January 12, 2009 ... solid tumors. , Under the terms of the agreement, Bayer ...
Cached Medicine Technology:Codexis Expands Collaboration with Teva 2Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet 2Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet 3Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet 4
The BioPro Basal Thumb joint is manufactured from Cobalt Chrome and is used to replace the Trapeziometacarpal joint....
... Fusion Screw is a headless ... of variable thread pitch and ... holding power. The Acutrak Fusion ... of the IP and DIP ...
The efficient choice for small joint replacement technology -- the Ascension Silicone MCP features a similar design to our PyroCarbon MCP and utilizes the same instrumentation for intra-operative fle...
A flexible intramedullary-stemmed, one-piece implant developed as an adjunct to resection arthroplasty to help restore function to hands disabled by rheumatoid, degenerative or post-traumatic arthrit...
Medicine Products: